Titan limps to Probuphine NDA with royalty trade and debt restructuring
This article was originally published in Scrip
Titan Pharmaceuticals explicitly pointed out during its 15 November quarterly earnings results that it had cash and cash equivalents of about $2.8 million at 30 September, as it readies an NDA submission with the US FDA for its lead candidate, Probuphine (buprenorphine in an ethylene-vinyl acetate rod), for opioid dependence, and seeks to interest a potential partner. The company’s cash crunch has been partly alleviated by news that it has entered into a $15 million royalty sale agreement with Deerfield Management.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.